Improved radioimmunolocalization of human tumor xenografts following subcutaneous delivery of monoclonal antibodies
dc.contributor.author | Beierwaltes, William H. | en_US |
dc.contributor.author | Laino, Linda | en_US |
dc.contributor.author | Schteingart, Miriam | en_US |
dc.contributor.author | Fisher, Susan J. | en_US |
dc.contributor.author | Wahl, Richard L. | en_US |
dc.date.accessioned | 2006-09-11T18:14:56Z | |
dc.date.available | 2006-09-11T18:14:56Z | |
dc.date.issued | 1988-01 | en_US |
dc.identifier.citation | Wahl, Richard L.; Laino, Linda; Fisher, Susan; Schteingart, Miriam; Beierwaltes, William H.; (1988). "Improved radioimmunolocalization of human tumor xenografts following subcutaneous delivery of monoclonal antibodies." European Journal of Nuclear Medicine 13(10): 530-536. <http://hdl.handle.net/2027.42/46825> | en_US |
dc.identifier.issn | 0340-6997 | en_US |
dc.identifier.issn | 1619-7089 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46825 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3371375&dopt=citation | en_US |
dc.description.abstract | The localization of a radiolabeled murine monoclonal antibody reactive with choriocarcinomas to human choriocarcinoma xenografts following intravenous and subcutaneous injection was evaluated by gamma scanning and tissue sampling. Tumor xenografts were established in the popliteal node region of athymic nude mice after repeated innoculations of the hind foot pads with BEWO choriocarcinoma cells. In dual label specific antibody studies, tumor/non tumor uptake ratios following subcutaneous (resulting in considerable intralymphatic uptake) injection of 131 I-5F9.3 were significantly higher than those achieved post simultaneous intravenous injection of 125 I-5F9.3. Double label experiments with 131 I-5F9.3 and a nonspecific antibody, 125 I-UPC-10, following subcutaneous injection, demonstrated that the high localization to popliteal region tumors was largely due to antibody specificity. Gamma scans following subcutaneous antibody administration of specific antibody to tumor bearing animals showed tumors soon after subcutaneous injection, at times earlier than those typically seen following intravenous delivery. Similar subcutaneous injections showed little normal nodal uptake in BALB/c control animals on gamma scans. No correlation was seen between tumor localization by specific antibody between the intravenous and intralymphatic routes, implying a difference in the mechanisms of tumor uptake of antibody by these two routes. The subcutaneous approach to antibody delivery offers advantages over intravenous delivery in tumors of human origin, including higher tumor/non tumor ratios and earlier imaging times. This was true even though these tumors were many times larger than normal lymph nodes. This subcutaneous delivery advantage should be exploitable in imaging nodal metastases of human tumors. | en_US |
dc.format.extent | 872868 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Lymph Node | en_US |
dc.subject.other | Radioimmunodetection | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Nuclear Medicine | en_US |
dc.subject.other | Choriocarcinoma | en_US |
dc.subject.other | Imaging / Radiology | en_US |
dc.subject.other | Monoclonal Antibody | en_US |
dc.subject.other | Lymphoscintigraphy | en_US |
dc.title | Improved radioimmunolocalization of human tumor xenografts following subcutaneous delivery of monoclonal antibodies | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Physics | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical Center, 1500 East Medical Center Drive, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical Center, 1500 East Medical Center Drive, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical Center, 1500 East Medical Center Drive, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical Center, 1500 East Medical Center Drive, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical Center, 1500 East Medical Center Drive, 48109, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 3371375 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46825/1/259_2004_Article_BF00256630.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00256630 | en_US |
dc.identifier.source | European Journal of Nuclear Medicine | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.